Over the next five years, the British pharmaceutical company GSK has committed to spending $30 billion (£22 billion) on research and manufacturing in the US. The funds, which were announced at the beginning of US President Donald Trump’s trip to the UK, will be used to build research labs, next-generation factories, and artificial intelligence (AI) in the US, according to GSK.
The investment, according to British Prime Minister Sir Keir Starmer, is a “powerful example” of the nations’ cooperation and will increase medicine development and generate new jobs. The action is a response to pressure from the Trump administration on pharmaceutical companies to shift their manufacturing to the United States. GSK stated in a statement that $1.2bn would be allocated to create a new factory in Pennsylvania to develop medicines for respiratory disorders and cancer. Next year is when construction is expected to begin.
Additionally, the funds will support new digital technology and artificial intelligence tools at GSK’s five American manufacturing facilities, including those in Maryland and North Carolina. According to the business, the remaining $30 billion would go into GSK’s supply chain and drug research initiatives. According to CEO Emma Walmsley, GSK intends to continue investing in its manufacturing base in the UK and allocating more than £1.5 billion annually for domestic research and development.
Also Read:
Nvidia is Accused of Breaking Anti-Monopoly Regulations in China
Rubio Meets with Netanyahu to Talk about the Consequences of Israel’s Strike in Qatar
